| This site is compliant with AIM Rule 26 Investor Relations Angel Biotechnology has created a unique offering in the Biopharmaceutical contract manufacturing arena. We have achieved this by providing clients with customized services to support their complete biopharmaceutical product development and clinical manufacture under one roof. This provides significant savings in time and cost to the client who does not have to transfer their project from one company to another, avoiding the risks that accompany such activities. In addition to our state-of-the-art clinical manufacturing facilities and process development laboratories, Angel has built a highly skilled management team to take the business forward. The Company now has the combination of resources and skills required to deliver on our business plan.
Angel's principal activity is the manufacture and supply of clinical grade materials for use in our clients drug development work. We have invested in a highly experienced management team and extremely flexible facilities which allow Angel to provide creative, low cost solutions for our clients. Our flexibility and service offering allow us to capitalize on new technologies and emerging trends within the industry; maximising market penetration. We are providing specialist solutions for cell based therapies e.g. cellular therapies and stem cells. The market for these therapies is expanding and Angel is in an excellent position to capitalize and become a market leader in providing such specialist services. We have a number of contracts moving into cGMP production where we have provided the client with a customized solution which meets their needs and accelerates their route to clinic. We expect to grow this part of our business significantly over the next few years, creating a differentiated offering for potential clients. For investor enquiries please contact: Gordon Sherriff Chief Operating Officer / Business Development Director
Tel: +44 (0) 131 445 6076
Email: gordon.sherriff@angelbio.com For News on Angel Biotechnology Holdings plc: Click here to read press releases. Site last updated 28th January 2010
|
